Inpatient Double-Blind Placebo-Controlled Withdrawal Study of 3 4-Diaminopyridine in Patients with Known Lambert-Eaton Myasthenic Syndrome
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this research study is to test whether the investigational drug, 3,4-diaminopyridine (3,4-DAP), improves the weakness associated with LEMS.
Description
The purpose of this research study is to test whether the investigational drug, 3,4-diaminopyridine (3,4-DAP), improves the weakness associated with LEMS.
Details
| Condition | Lambert-Eaton Myasthenic Syndrome |
|---|---|
| Age | 18years - 100years |
| Clinical Study Identifier | TX2208 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.